컨티넘 테라퓨틱스(CTNM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $13.53 (+2.42%), 시가총액 $0.50B, 52주 최저~최고 $3.40 ~ $16.00.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November
컨티넘 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
컨티넘 테라퓨틱스의 현재 주가는 $13.53 (+2.42%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
컨티넘 테라퓨틱스의 시가총액은 약 $0.50B입니다.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the